Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Biotechnology
Roche ends development of SMA drug olesoxime
by Lisa M. Jarvis
June 10, 2018
| A version of this story appeared in
Volume 96, Issue 24
Roche has ended development of olesoxime, a small molecule designed to protect nerve cells in spinal muscular atrophy. In 2015, the big pharma firm paid roughly $140 million to acquire olesoxime from Trophos, and it had hoped to begin a Phase III study of the compound later this year. But in a letter to SMA patient advocacy groups, Roche said it had struggled with the formulation of the drug. And because of newly available treatments for SMA, the company chose to end its efforts in the area.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter